News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 150
- Sources here
- 9
- Companies here
- 7
Search results
Stored financial headlines
Active search
150 matching headlines
Ticker or company: DRUGMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Drugs Made In America Acquisition II Corp. Revenue Breakdown – BOATS:DMIIU
This article provides a brief overview of Drugs Made In America Acquisition II Corp. (DMIIU) financial information available on TradingView. It indicates that the market is closed and there are no trades for the company. The page focuses on fundamental data, statements, statistics, dividends, …
DMAA
main company
Sharemaestro market context
Trend signal active
52 weeks +4.3% · Next-week setup positive 71.6%
Perceptive Advisors LLC Sells 71,746 Shares of Bright Minds Biosciences Inc. $DRUG
Perceptive Advisors LLC reduced its stake in Bright Minds Biosciences (NASDAQ:DRUG) by 16% in the first quarter, selling 71,746 shares and retaining 377,544 shares valued at $27.5 million. Despite this, institutional investors collectively own about 40.5% of the company's stock, with several firms increasing …
DRUG
main company
Sharemaestro market context
Price below Trend Line
52 weeks +73.9% · Next-week setup negative 43.1%
Bright Minds Biosciences Inc. $DRUG Shares Bought by Vivo Capital LLC
Vivo Capital LLC increased its stake in Bright Minds Biosciences (NASDAQ:DRUG) by 11.1% in the first quarter, now holding 557,172 shares valued at $40.7 million. Several other institutional investors also increased their positions, bringing total institutional ownership to 40.52%. The company reported better-than-expected quarterly …
DRUG
main company
Sharemaestro market context
Price below Trend Line
52 weeks +73.9% · Next-week setup negative 43.1%
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Rating of "Buy" from Brokerages
Bright Minds Biosciences Inc. (NASDAQ:DRUG) has a consensus "Buy" rating from seven analysts, with an average 12-month price target of $143.83. The company, which is developing psychedelic-inspired treatments for mental health and neurodegenerative conditions, reported a quarterly loss of $0.80 per share, beating analyst …
DRUG
main company
Sharemaestro market context
Price below Trend Line
52 weeks +73.9% · Next-week setup negative 43.1%
Bright Minds Biosciences Inc (DRUG) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical data on dividends and stock splits for Bright Minds Biosciences Inc (DRUG). It indicates that no dividends have been distributed in the past five years. The company executed several 5-for-1 merger-related stock splits on June 22, 2023.
DRUG
main company
Sharemaestro market context
Price below Trend Line
52 weeks +73.9% · Next-week setup negative 43.1%
ADAR1 Capital Management LLC Has $2.47 Million Stock Position in Bright Minds Biosciences Inc. $DRUG
ADAR1 Capital Management LLC significantly increased its stake in Bright Minds Biosciences Inc. (NASDAQ:DRUG) by 868.6% in the first quarter, now holding 33,900 shares valued at $2.47 million. Institutional investors collectively own 40.52% of the company, which reported a narrower-than-expected quarterly loss of $0.80 …
DRUG
main company
Sharemaestro market context
Price below Trend Line
52 weeks +73.9% · Next-week setup negative 43.1%
Bright Minds Biosciences Market Sentiment
This article analyzes Bright Minds Biosciences (DRUG) market sentiment based on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from 10 analysts with an average price target of $128, a 12.6% short float, and provides a detailed history …
DRUG
main company
Sharemaestro market context
Price below Trend Line
52 weeks +73.9% · Next-week setup negative 43.1%
DRUG|Bright Minds Biosciences Inc|Price:70.680|Chg%:-1.280
This article provides an analysis of Bright Minds Biosciences Inc. (DRUG) through TradingKey's stock score system. It details the methodologies used to generate scores across various dimensions including financial health, valuation, earnings forecasts, price momentum, institutional confidence, and risk management. However, it explicitly states …
DRUG
main company
Sharemaestro market context
Price below Trend Line
52 weeks +73.9% · Next-week setup negative 43.1%
Bright Minds Biosciences Inc (DRUG) Cash Flow
This article provides a detailed cash flow statement for Bright Minds Biosciences Inc (DRUG), covering operating, investing, and financing activities on a quarterly and annual basis. It presents extensive historical financial data, including net income, changes in working capital, and various components of cash …
DRUG
main company
Sharemaestro market context
Price below Trend Line
52 weeks +73.9% · Next-week setup negative 43.1%
Drugs Made In America Acquisition Corp (DMAA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on the dividend and stock split history for Drugs Made In America Acquisition Corp (DMAA). It notes that no dividends have been distributed over the past five years. The page also displays current stock information, including its price, market cap, …
DMAA
main company
Sharemaestro market context
Trend signal active
52 weeks +4.3% · Next-week setup positive 71.6%
Drugs Made In America Acquisition Corp (DMAA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Drugs Made In America Acquisition Corp (DMAA), focusing on its P/E ratio, P/B ratio, and fair value. As of July 24th, DMAA's stock was trading at $10.709 with a market cap of $361.09 million and a TTM …
DMAA
main company
Sharemaestro market context
Trend signal active
52 weeks +4.3% · Next-week setup positive 71.6%
40,000 Shares in Bright Minds Biosciences Inc. $DRUG Acquired by Orbimed Advisors LLC
Orbimed Advisors LLC acquired 40,000 shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG), a stake valued at approximately $2.9 million, contributing to institutional investors' 40.52% ownership. Analysts maintain a "Buy" rating with an average target price of $143.83, some raising targets and Zacks upgrading the …
DRUG
main company
Sharemaestro market context
Price below Trend Line
52 weeks +73.9% · Next-week setup negative 43.1%
Bright Minds Biosciences Inc (DRUG) Institutional Confidence
This article from TradingKey focuses on the institutional confidence in Bright Minds Biosciences Inc (DRUG). It lists the top institutional shareholders, their shareholdings, and the percentage change in their positions. The company's stock information, including market cap and recent price movements, is also provided.
DRUG
main company
Sharemaestro market context
Price below Trend Line
52 weeks +73.9% · Next-week setup negative 43.1%
Drugs Made In America Acquisition Corp (DMAA) Balance Sheet
This article provides the balance sheet for Drugs Made In America Acquisition Corp (DMAA), detailing its quarterly and annual financial health. It includes key financial metrics such as cash, assets, liabilities, and shareholders' equity, allowing for an analysis of the company's fundamentals and liquidity. …
DMAA
main company
Sharemaestro market context
Trend signal active
52 weeks +4.3% · Next-week setup positive 71.6%
Drugs Made In America Acquisition Corp (DMAA) Cash Flow
This article provides an in-depth look at the cash flow statement for Drugs Made In America Acquisition Corp (DMAA), detailing its operating, investing, and financing activities. It presents both annual and quarterly data, highlighting significant changes such as a notable increase in operating cash …
DMAA
main company
Sharemaestro market context
Trend signal active
52 weeks +4.3% · Next-week setup positive 71.6%
TradingKey
This article provides the income statement for Drugs Made In America Acquisition Corp (DMAA), including quarterly and annual financial data. It details key metrics such as operating expenses, operating profit, net non-operating interest income, income before and after tax, net income, and earnings per …
DMAA
main company
Sharemaestro market context
Trend signal active
52 weeks +4.3% · Next-week setup positive 71.6%
Drugs Made In America Acquisition Corp
This article provides a company overview for Drugs Made In America Acquisition Corp (DMAA), including its stock performance and market capitalization. It notes that relevant revenue breakdown data by business segment and region have not yet been disclosed by the company. The page also …
DMAA
main company
Sharemaestro market context
Trend signal active
52 weeks +4.3% · Next-week setup positive 71.6%
DMAA|Drugs Made In America Acquisition Corp|Price:10.681|Chg%:-0.009
This article provides a detailed financial overview of Drugs Made In America Acquisition Corp (DMAA), a blank check company focused on the pharmaceutical industry. It presents real-time stock quotes, key financial figures, technical indicators, and shareholder information. The company has not yet disclosed relevant …
DMAA
main company
Sharemaestro market context
Trend signal active
52 weeks +4.3% · Next-week setup positive 71.6%
Walleye Capital LLC Has $3.92 Million Holdings in Bright Minds Biosciences Inc. $DRUG
Walleye Capital LLC significantly increased its stake in Bright Minds Biosciences Inc. (NASDAQ:DRUG) by 108% in the first quarter, now holding 53,706 shares valued at $3.92 million. Other institutional investors also boosted their positions, with hedge funds and institutions collectively owning 40.52% of the …
DRUG
main company
Sharemaestro market context
Price below Trend Line
52 weeks +73.9% · Next-week setup negative 43.1%
Bright Minds Biosciences (NASDAQ:DRUG) Upgraded at Zacks Research
Zacks Research has upgraded Bright Minds Biosciences (NASDAQ:DRUG) from "hold" to "strong-buy," contributing to a consensus "Buy" rating among analysts with a target price of $143.83. This upgrade follows the company's recent strong quarterly earnings report, where its EPS of ($0.80) surpassed estimates of …
DRUG
main company
Sharemaestro market context
Price below Trend Line
52 weeks +73.9% · Next-week setup negative 43.1%